CDT

S-3 - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio, proprietary solid-form intellectual property and artificial intelligence-driven indication discovery. The Company believes it is uniquely positioned through a combination of high-quality clinical assets, proprietary chemistry, and advanced data-driven capabilities to generate long-term shareholder value through a capital-efficient, out-licensing model. CDT continues to evaluate and advance its portfolio of asse

10-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the publication of its research paper titled "PRISM: cross-species connectivity mapping of plant intervention and stress signatures for translational agriculture." CDT holds a 20% equity interest in Sarborg and believes this development represents a meaningful extension of Sarborg's proprietary Signature Intelligence platform beyond its initial pharmaceutical focus into the agrichemical and broader industrial biology sectors. PRISM represents a novel framework for applying connectivity mapping to

424B5 - CDT Equity Inc. (0001896212) (Filer)

NT 10-K - CDT Equity Inc. (0001896212) (Filer)

4 - CDT Equity Inc. (0001896212) (Issuer)

3 - CDT Equity Inc. (0001896212) (Issuer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the filing of two new patent applications that further expand the Company's intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. CDT believes these developments may underpin a second-generation tapinarof product with enhance

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on March 26, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company's common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market ("Nasdaq") at market open under the existing

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that it has completed initial signature mapping of its asset portfolio against Sarborg Limited's recently curated rare disease database, identifying multiple high-potential opportunities across a range of rare and underserved indications. The analysis, conducted using Sarborg's proprietary AI Signature Agent platform, evaluated CDT's portfolio of assets, including its solid-form patent portfolio and its licensed AstraZeneca compounds AZD1656 and AZD5658, against a database of approximately 1,700 rare disease signatures. The Company reports t

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, 2026, were duly passed by the stockholders. "Following the successful passing of all the proposals at yesterday's Special Meeting, CDT Equity continues to transform through its $123M investment in Sarborg, the continued expansion of its IP portfolio, potential access to significant new capital and a carefully controlled annual overhead of less than $8 million," said Dr. Andrew Regan, Chief Executive Officer. "Utilizing cutting edge AI and an

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform through the curation of a rare disease signature database. Sarborg announced that it has curated a database containing approximately 1,700 rare disease signatures, building upon its existing disease signature library of more than 1,600 conditions, as well as its agrochemical and bacterial signature datasets previously announced. According to Sarborg, structuring rare diseases as machine-interpretable biological signatures enables rapid an

8-K - CDT Equity Inc. (0001896212) (Filer)

DEF 14A - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today notes the announcement issued by Sarborg Limited ("Sarborg") regarding the filing of a U.S. provisional patent application relating to its proprietary AI Signature Agent. CDT holds a 20% equity stake in Sarborg and views this filing as an important step in strengthening and formalising Sarborg's intellectual property position. Sarborg announced that a provisional patent application was filed with the United States Patent and Trademark Office on February 12, 2026, and has been assigned United States Patent Application No. 63/981,801. The application re

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") advances multiple initiatives designed to enhance shareholder value and expand its strategic footprint. The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT remains engaged in ongoing evaluation and out-licensing discussions and continues to assess pathways to maximize the commercial and strategic potential of these assets. The Company believes this diversifi

8-K - CDT Equity Inc. (0001896212) (Filer)

PRE 14A - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement issued this morning by Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform beyond pharmaceuticals into bacteria and agrochemicals. CDT holds a significant 20% equity stake in Sarborg and views this expansion as a meaningful strategic development in the continued evolution of Sarborg's cross-industry signature intelligence platform. Sarborg announced that, following the successful deployment of its Pharmaceutical Signature Agent, it has curated approximately 4,500 agrochemical signatures and app

4 - CDT Equity Inc. (0001896212) (Issuer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures

424B3 - CDT Equity Inc. (0001896212) (Filer)